Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm
Mandate

Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

April 01, 2020

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.

Xspray Pharma is a product development company that develops improved and generic versions of marketed drugs, primarily protein kinase inhibitors for the treatment of cancer. Xspray has multiple product candidates in clinical development.

Vinge’s team has primarily consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Joel Magnusson, Maria Schultzberg, Stojan Arnerstål and Henrik Wastenson.

Sanctions update 22 July

 Further to our previous sanctions updates of 25 February, 3 March, 11 March, 16 March , 14 April and June 8, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
July 26, 2022

A new EU instrument for international procurement (IPI)

 On 17 June 2022, the Council adopted a regulation on a new instrument for international procurement (“IPI”), following the formal adoption of the IPI at the European Parliament plenary session on 9 June 2022. The general objective of the IPI is to create reciprocity in the access to international public procurement markets by enabling the Commission to undertake investigations and adopt measures to open and improve access to third-country public procurement and concession markets.
July 11, 2022

Vinge top ranked within intellectual property law

 Vinge’s IP practice group is once again top ranked in IAM’s annual ranking Patent 1000. Håkan Borgenhäll, Malin Malm Waerme and Stojan Arnerstål also receive individual recommendations.
July 06, 2022